70 related articles for article (PubMed ID: 7675451)
1. Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor.
Fournier E; Dubreuil P; Birnbaum D; Borg JP
Oncogene; 1995 Sep; 11(5):921-31. PubMed ID: 7675451
[TBL] [Abstract][Full Text] [Related]
2. Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase.
Borg JP; deLapeyrière O; Noguchi T; Rottapel R; Dubreuil P; Birnbaum D
Oncogene; 1995 Mar; 10(5):973-84. PubMed ID: 7898938
[TBL] [Abstract][Full Text] [Related]
3. Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling.
Fournier E; Blaikie P; Rosnet O; Margolis B; Birnbaum D; Borg JP
Oncogene; 1999 Jan; 18(2):507-14. PubMed ID: 9927207
[TBL] [Abstract][Full Text] [Related]
4. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors.
Pajusola K; Aprelikova O; Pelicci G; Weich H; Claesson-Welsh L; Alitalo K
Oncogene; 1994 Dec; 9(12):3545-55. PubMed ID: 7970715
[TBL] [Abstract][Full Text] [Related]
5. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
Saucier C; Papavasiliou V; Palazzo A; Naujokas MA; Kremer R; Park M
Oncogene; 2002 Mar; 21(12):1800-11. PubMed ID: 11896612
[TBL] [Abstract][Full Text] [Related]
6. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts.
Pajusola K; Aprelikova O; Armstrong E; Morris S; Alitalo K
Oncogene; 1993 Nov; 8(11):2931-7. PubMed ID: 7692369
[TBL] [Abstract][Full Text] [Related]
7. Characterization of murine Flt4 ligand/VEGF-C.
Fitz LJ; Morris JC; Towler P; Long A; Burgess P; Greco R; Wang J; Gassaway R; Nickbarg E; Kovacic S; Ciarletta A; Giannotti J; Finnerty H; Zollner R; Beier DR; Leak LV; Turner KJ; Wood CR
Oncogene; 1997 Jul; 15(5):613-8. PubMed ID: 9247316
[TBL] [Abstract][Full Text] [Related]
8. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.
Fixman ED; Naujokas MA; Rodrigues GA; Moran MF; Park M
Oncogene; 1995 Jan; 10(2):237-49. PubMed ID: 7838524
[TBL] [Abstract][Full Text] [Related]
9. N-Shc: a neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway.
Nakamura T; Sanokawa R; Sasaki Y; Ayusawa D; Oishi M; Mori N
Oncogene; 1996 Sep; 13(6):1111-21. PubMed ID: 8808684
[TBL] [Abstract][Full Text] [Related]
10. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
[TBL] [Abstract][Full Text] [Related]
11. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
Shibuya M; Seetharam L; Ishii Y; Sawano A; Gotoh N; Matsushime H; Yamaguchi S
Princess Takamatsu Symp; 1994; 24():162-70. PubMed ID: 8983073
[TBL] [Abstract][Full Text] [Related]
12. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.
Boerner JL; Danielsen AJ; Lovejoy CA; Wang Z; Juneja SC; Faupel-Badger JM; Darce JR; Maihle NJ
Oncogene; 2003 Oct; 22(43):6679-89. PubMed ID: 14555981
[TBL] [Abstract][Full Text] [Related]
13. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
14. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor.
Galland F; Karamysheva A; Pebusque MJ; Borg JP; Rottapel R; Dubreuil P; Rosnet O; Birnbaum D
Oncogene; 1993 May; 8(5):1233-40. PubMed ID: 8386825
[TBL] [Abstract][Full Text] [Related]
15. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
Vempati S; Reindl C; Wolf U; Kern R; Petropoulos K; Naidu VM; Buske C; Hiddemann W; Kohl TM; Spiekermann K
Clin Cancer Res; 2008 Jul; 14(14):4437-45. PubMed ID: 18628457
[TBL] [Abstract][Full Text] [Related]
16. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.
Pajusola K; Aprelikova O; Korhonen J; Kaipainen A; Pertovaara L; Alitalo R; Alitalo K
Cancer Res; 1992 Oct; 52(20):5738-43. PubMed ID: 1327515
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
[TBL] [Abstract][Full Text] [Related]
18. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor.
Moscatello DK; Montgomery RB; Sundareshan P; McDanel H; Wong MY; Wong AJ
Oncogene; 1996 Jul; 13(1):85-96. PubMed ID: 8700557
[TBL] [Abstract][Full Text] [Related]
19. The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R.
Jones N; Dumont DJ
Oncogene; 1998 Sep; 17(9):1097-108. PubMed ID: 9764820
[TBL] [Abstract][Full Text] [Related]
20. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
